Nifty
:
23123.65
Sensex
:
74616.58
155.40 (0.68%)
509.73 (0.69%)
Nifty
Sensex
:
:
23123.65
74616.58
155.40 (0.68%)
509.73 (0.69%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
77/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
2114.10
07-Apr-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2100
  •  2138
  •  2068.2
  •  2104.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  387544
  •  818057373.6
  •  2297.9
  •  1336

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 59,638.91
  • 55.99
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 57,840.18
  • 0.12%
  • 5.97

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.16%
  • 10.77%
  • FII
  • DII
  • Others
  • 19.2%
  • 18.93%
  • 2.29%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.83
  • 4.01
  • 4.77

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.05
  • 2.44
  • 7.54

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.49
  • 1.54
  • 10.03

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.64
  • 13.75
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.92
  • 3.25
  • 4.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.21
  • 12.12
  • 15.51

Earnings Forecasts:

(Updated: 04-04-2026)
Description
2024
2025
2026
2027
Adj EPS
37.11
85.11
82.94
95.97
P/E Ratio
56.97
24.84
25.49
22.03
Revenue
13145.8
15418
16391.4
18140.1
EBITDA
2379.61
3143.32
3647.83
4204.48
Net Income
1047.1
1871.39
2309.27
2707.71
ROA
6.89
13.49
16.03
P/B Ratio
6.74
5.73
4.78
4.02
ROE
12.54
14.71
19.92
19.8
FCFF
-1725.82
533.13
1218.79
1760.32
FCFF Yield
-2.87
0.89
2.03
2.93
Net Debt
-44.08
-522.97
-1577.22
-2907.92
BVPS
313.6
368.77
442.36
525.25

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
3,900.62
3,387.55
15.15%
6,046.87
3,433.80
76.10%
3,264.44
3,244.19
0.62%
3,256.21
3,062.95
6.31%
Expenses
3,030.87
2,787.32
8.74%
3,687.32
2,831.88
30.21%
2,683.92
2,655.97
1.05%
2,695.18
2,558.61
5.34%
EBITDA
869.75
600.23
44.90%
2,359.55
601.91
292.01%
580.52
588.21
-1.31%
561.03
504.34
11.24%
EBIDTM
22.30%
17.72%
39.02%
17.53%
17.78%
18.13%
17.23%
16.47%
Other Income
44.46
31.13
42.82%
200.63
39.42
408.95%
26.44
31.49
-16.04%
11.68
773.16
-98.49%
Interest
41.43
52.29
-20.77%
66.46
48.48
37.09%
58.23
39.58
47.12%
66.71
148.56
-55.10%
Depreciation
154.45
122.74
25.84%
141.20
120.28
17.39%
129.93
117.79
10.31%
125.20
151.34
-17.27%
PBT
534.00
456.33
17.02%
967.40
472.57
104.71%
95.58
462.33
-79.33%
7.97
530.83
-98.50%
Tax
130.77
108.30
20.75%
356.97
118.09
202.29%
48.61
122.10
-60.19%
3.59
1,769.47
-99.80%
PAT
403.23
348.03
15.86%
610.43
354.49
72.20%
46.97
340.24
-86.20%
4.38
-1,238.65
-
PATM
10.34%
10.27%
10.10%
10.32%
1.44%
10.49%
0.13%
-40.44%
EPS
14.29
12.33
15.90%
21.63
12.55
72.35%
1.66
12.06
-86.24%
0.16
-43.17
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
16,468.14
13,321.74
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
Net Sales Growth
25.44%
12.77%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
 
Cost Of Goods Sold
4,664.14
4,287.37
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
Gross Profit
11,804.00
9,034.37
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
GP Margin
71.68%
67.82%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
Total Expenditure
12,097.29
10,970.36
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
Power & Fuel Cost
-
131.40
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
120.47
% Of Sales
-
0.99%
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
Employee Cost
-
3,022.06
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
% Of Sales
-
22.69%
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
Manufacturing Exp.
-
987.39
1,012.86
633.51
784.63
638.74
669.50
725.16
648.59
546.75
503.49
% Of Sales
-
7.41%
8.57%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
6.66%
General & Admin Exp.
-
1,457.32
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
944.30
% Of Sales
-
10.94%
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
12.49%
Selling & Distn. Exp.
-
1,051.00
892.72
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
% Of Sales
-
7.89%
7.56%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
Miscellaneous Exp.
-
33.81
54.46
48.49
78.68
121.44
47.19
33.29
314.55
88.52
892.67
% Of Sales
-
0.25%
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
EBITDA
4,370.85
2,351.38
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
EBITDA Margin
26.54%
17.65%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
Other Income
283.21
113.72
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
20.00
Interest
232.83
207.06
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
178.88
Depreciation
550.78
486.01
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
234.28
PBT
1,604.95
1,772.03
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
Tax
539.94
352.07
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
300.94
Tax Rate
33.64%
25.16%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
PAT
1,065.01
1,047.09
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
PAT before Minority Interest
1,065.08
1,047.14
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
Minority Interest
0.07
-0.05
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
PAT Margin
6.47%
7.86%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
PAT Growth
643.68%
-
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
 
EPS
37.74
37.10
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29
26.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
8,849.44
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Total Reserves
8,812.16
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
Non-Current Liabilities
109.35
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
512.70
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,967.02
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
Trade Payables
2,579.53
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
Other Current Liabilities
1,081.54
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
Short Term Borrowings
1,681.49
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
Short Term Provisions
624.46
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
134.03
Total Liabilities
14,925.44
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
Net Block
4,486.82
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
Gross Block
10,364.92
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
Accumulated Depreciation
5,878.10
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
Non Current Assets
5,629.98
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
Capital Work in Progress
834.83
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
Non Current Investment
56.35
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
17.20
Long Term Loans & Adv.
242.74
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
69.99
Other Non Current Assets
9.23
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
Current Assets
9,295.47
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
3,028.53
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
Sundry Debtors
3,341.95
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
Cash & Bank
1,705.23
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
Other Current Assets
1,219.76
178.21
316.61
297.46
1,371.54
1,147.78
1,312.40
1,391.61
1,273.61
986.77
Short Term Loans & Adv.
1,074.79
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
594.89
Net Current Assets
3,328.44
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
Total Assets
14,925.45
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
-827.60
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
PBT
1,399.21
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
Adjustment
982.01
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
Changes in Working Capital
-2,528.69
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
Cash after chg. in Working capital
-147.47
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-680.13
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
2.09
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
Net Fixed Assets
-307.30
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
Net Investments
-2,230.12
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
Others
2,539.51
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
Cash from Financing Activity
787.04
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
Net Cash Inflow / Outflow
-38.46
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
Opening Cash & Equivalents
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
Closing Cash & Equivalent
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
313.28
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
ROA
7.42%
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
ROE
12.56%
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
ROCE
16.16%
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
Fixed Asset Turnover
2.94
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
1.96
Receivable days
32.34
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
119.39
Inventory Days
34.46
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
67.68
Payable days
217.75
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
117.03
Cash Conversion Cycle
-150.94
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
Total Debt/Equity
0.25
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
Interest Cover
7.76
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28
6.84

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Glenmark Pharmaceuticals launches GLIPIQ in India
    23rd Mar 2026, 10:21 AM

    The expected weekly cost of treatment with GLIPIQ vials range from Rs 325 to Rs 440, significantly lowering the cost barrier to initiate GLP-1 therapy in India

    Read More
  • Glenmark Pharmaceuticals gets final nod for Fluticasone Propionate Nasal Spray
    19th Mar 2026, 11:52 AM

    Fluticasone Propionate Nasal Spray USP, 50 mcg per spray will be distributed in the U.S. by Glenmark Therapeutics Inc., USA

    Read More
  • Glenmark Pharmaceuticals’ arm launches Milnacipran Hydrochloride tablets
    19th Mar 2026, 10:22 AM

    The Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market achieved annual sales of around $102.9 million

    Read More
  • Glenmark Pharma’s arm to launch Potassium Phosphates Injection
    16th Mar 2026, 12:12 PM

    Glenmark Pharmaceuticals Inc., USA is all set to launch of Potassium Phosphates Injection in March 2026

    Read More
  • Glenmark Pharmaceuticals’ arm gets USFDA’s nod for Fluticasone Propionate Inhalation Aerosol
    4th Mar 2026, 11:42 AM

    Glenmark’s Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026

    Read More
  • Glenmark Pharmaceuticals’ arm to launch Sodium Phosphates Injection
    27th Feb 2026, 11:40 AM

    Glenmark will begin distribution in April 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.